The increased incidence and prevalence of congestive heart failure place a high priority on novel treatment strategies. Left ventricular ejection fraction remains the single most valuable measurement providing both diagnostic and prognostic insights. The most systematic approach to heart failure involves an objective assessment of functional disability, to include exercise tests such as a 6-minute walk under standardized conditions. Left ventricular dysfunction incites a host of neurohumoral compensations that are of fundamental importance in the heart failure syndrome expression. Both vasoconstrictor and vasodilator neurohormones are stimulated and provide new therapeutic opportunities. The therapeutic approach to heart failure begins with a strong emphasis on prevention, patient education, and self-participation in therapy with respect to both its monitoring and adjustment. Diuretics remain a mainstay of therapy but, in the face of severe heart failure, may become ineffectual, requiring constant infusion of loop-active diuretics, combination diuretics, or diuretics in association with concomitant low-dose dopamine infusion. Vasodilator therapy has been an important advance: combination hydralazine and nitrate therapy was initially shown to be efficacious in improving survival, and more recently, angiotensin-converting enzyme (ACE) inhibitors, in the form of enalapril, have shown incremental benefit on survival over this combination. Interestingly, there is now evidence from both SOLVD and SAVE to demonstrate an unexpected and, as yet, unexplained reduction in the frequency of both unstable angina and myocardial infarction. Although, on balance, the weight of evidence concerning the long-term efficacy of inotropic agents has been disappointing, especially as it relates to their unfavorable effects on survival, recent information on vesnarinone, an agent with a complex and diversified mechanism of action, suggests that with appropriate doses, improved symptoms and survival are possible. A substantial amount of new information from randomized placebo-controlled trials attests to the symptomatic relief, hemodynamic improvement, and gain in exercise performance achieved by digoxin. A long-term survival study is ongoing to assess its effects on mortality. j3-Blockers, especially metoprolol, appear beneficial in some patients with heart failure, possibly related to their reduction in sympathetic nervous activity and restoration of J3-receptor population, with resultant improved contractile performance, enhanced myocardial relaxation, and overall increase in cardiac efficiency. Based on available evidence, the best contemporary approach to treatment involves the use of ACE inhibitors coupled with diuretic therapy, either continuous or intermittent, to relieve central or peripheral congestion. The addition of digoxin or a hydralazine nitrate combination is a logical next step, with commencement of low-dose 13-blocker a reasonable option. The residual mortality in the treatment groups of large-scale, contemporary, randomized clinical trials of novel therapy suggests substantial continuing need for the development of novel treatment strategies. (Circulation. 1994;88:2941-2952 KEY WORDs * heart failure, congestive * diuretics * vasodilation * inotropic agents Medicines are nothing in themselves, ifnotproperly used, but the very hands of the gods, if employed with reason and prudence. Herophilus (floruit 300 BC) Background There can be no doubt that therapeutic advances in heart failure must constitute a central health care priority, given the increasing incidence and prevalence of the disorder and the enormous associated socioeconomic implications. Framingham data indicate that the prevalence among those aged 50 to 59 years is 1% of the US population and that this doubles with each decade of age increment thereafter.' It is conservatively estimated that more than 2 million Americans are affected with heart failure, with more than 400 000 new cases occurring annually and a resultant 900 000 hospitalizations, which translates into an annual estimated cost of nearly $9 billion.1'2 When these data are placed in the context of a 5-year mortality of =50% and the current shift toward an aging population, the challenge looms large.3 This is further emphasized by new survival data from patients with overt congestive heart failure in the Framingham Heart Study that indicate persisting high lethality (age adjusted) without significant temporal prognostic improvement during the 40-year period 1948 through 1988.4 The extraordinary growth in our understanding of the pathophysiology, natural history, and epidemiology of 2942 Circulation Vol 88, No 6 December 1993 heart failure within the past decade has spawned, on the one hand, a stunning array of novel treatment strategies and on the other, a sober reevaluation of therapeutic objectives. During this period, a precise definition of heart failure has remained elusive. Physicians have relied on the time-honored general and all-inclusive portrait of heart failure as characterized by an inadequacy of the heart, usually in association with elevated central cardiac filling pressures, to meet the metabolic demands of peripheral organs and tissues either at rest or during stress. Although left ventricular dysfunction remains the centerpiece around which heart failure concepts are modeled, it evokes a dramatic heterogeneity of compensatory responses that involve the heart, other vital organs, the peripheral vasculature, and skeletal muscle: each of these may be variably modulated by a complex and still incompletely understood neurohormonal system. Moreover, it is these compensatory responses that appear to govern modes of clinical presentation, response to therapy, and prognosis. The single most valuable measurement in heart failure remains the left ventricular ejection fraction.56 Despite its importance in providing both diagnostic and prognostic insights, ejection fraction bears an imperfect relation to symptoms, exercise tolerance, and response to therapy. This dissociation may relate in part to (1) coexistent diastolic dysfunction that rises in prevalence with increasing age and may escape conventional noninvasive assessment; (2) peripheral circulatory and skeletal muscle adaptations; and (3) neurohumoral profile.7-9 A substantial proportion, ie, between one third and one half of heart failure patients, die suddenly, and this appears especially true if they have underlying coronary artery disease. Whereas there is an important relation between baseline left ventricular ejection fraction and ultimate survival, the proportion of patients dying suddenly tends to be greater in patients with less severe manifestations of heart failure; moreover, the presence of ventricular arrhythmia is associated with reduced survival and an increased propensity for sudden death.10-1' Male sex, advanced age, and diabetes in women all portend worsened survival.4 Heart failure also imposes an enormous burden of morbidity, with frequent exacerbations requiring hospitalization, increased risk of acute myocardial infarction and unstable angina, pulmonary embolism, and a fourfold increase in the risk of cerebrovascular accident.' Prevention of these and other complications is a fundamental component of effective therapy. The traditional goal of heart failure therapy has been to enhance exercise tolerance and reduce symptoms in those patients with functional disability. In 1986, the VHeFT-1 study extended this goal by demonstrating improved survival with vasodilator therapy using a combination of hydralazine and isosorbide dinitrate.19 Whereas subsequent studies20-22 have persuasively indicated that pharmacologic therapy can improve survival in heart failure, others have cogently and unhappily demonstrated the capacity for treatment to increase morbidity and shorten survival, thereby highlighting the potential for therapeutic misadventure.23-25 Ironically, it is now evident that in patients with advanced symptoms, treatment strategies exist that may produce symptomatic benefit on the one hand yet impair survival on the other.
Medicines are nothing in themselves, ifnotproperly used, but the very hands of the gods, if employed with reason and prudence. Herophilus (floruit 300 BC) Background There can be no doubt that therapeutic advances in heart failure must constitute a central health care priority, given the increasing incidence and prevalence of the disorder and the enormous associated socioeconomic implications. Framingham data indicate that the prevalence among those aged 50 to 59 years is 1% of the US population and that this doubles with each decade of age increment thereafter.' It is conservatively estimated that more than 2 million Americans are affected with heart failure, with more than 400 000 new cases occurring annually and a resultant 900 000 hospitalizations, which translates into an annual estimated cost of nearly $9 billion.1'2 When these data are placed in the context of a 5-year mortality of =50% and the current shift toward an aging population, the challenge looms large.3 This is further emphasized by new survival data from patients with overt congestive heart failure in the Framingham Heart Study that indicate persisting high lethality (age adjusted) without significant temporal prognostic improvement during the 40-year period 1948 through 1988. 4 The extraordinary growth in our understanding of the pathophysiology, natural history, and epidemiology of heart failure within the past decade has spawned, on the one hand, a stunning array of novel treatment strategies and on the other, a sober reevaluation of therapeutic objectives. During this period, a precise definition of heart failure has remained elusive. Physicians have relied on the time-honored general and all-inclusive portrait of heart failure as characterized by an inadequacy of the heart, usually in association with elevated central cardiac filling pressures, to meet the metabolic demands of peripheral organs and tissues either at rest or during stress. Although left ventricular dysfunction remains the centerpiece around which heart failure concepts are modeled, it evokes a dramatic heterogeneity of compensatory responses that involve the heart, other vital organs, the peripheral vasculature, and skeletal muscle: each of these may be variably modulated by a complex and still incompletely understood neurohormonal system. Moreover, it is these compensatory responses that appear to govern modes of clinical presentation, response to therapy, and prognosis. The single most valuable measurement in heart failure remains the left ventricular ejection fraction. 56 Despite its importance in providing both diagnostic and prognostic insights, ejection fraction bears an imperfect relation to symptoms, exercise tolerance, and response to therapy. This dissociation may relate in part to (1) coexistent diastolic dysfunction that rises in prevalence with increasing age and may escape conventional noninvasive assessment; (2) peripheral circulatory and skeletal muscle adaptations; and (3) neurohumoral profile.7-9 A substantial proportion, ie, between one third and one half of heart failure patients, die suddenly, and this appears especially true if they have underlying coronary artery disease. Whereas there is an important relation between baseline left ventricular ejection fraction and ultimate survival, the proportion of patients dying suddenly tends to be greater in patients with less severe manifestations of heart failure; moreover, the presence of ventricular arrhythmia is associated with reduced survival and an increased propensity for sudden death.10-1' Male sex, advanced age, and diabetes in women all portend worsened survival.4 Heart failure also imposes an enormous burden of morbidity, with frequent exacerbations requiring hospitalization, increased risk of acute myocardial infarction and unstable angina, pulmonary embolism, and a fourfold increase in the risk of cerebrovascular accident.' Prevention of these and other complications is a fundamental component of effective therapy.
For purposes of addressing contemporary management of heart failure, this review of therapeutic advances will be limited to patients with systolic dysfunction as defined by a left ventricular ejection fraction <45%. The lack of a uniformly accepted definition of heart failure and the myriad of patient subsets within this heterogeneous diagnosis present a considerable challenge to the practicing physician selecting therapy. ' The traditional goal of heart failure therapy has been to enhance exercise tolerance and reduce symptoms in those patients with functional disability. In 1986, the VHeFT-1 study extended this goal by demonstrating improved survival with vasodilator therapy using a combination of hydralazine and isosorbide dinitrate. 19 Whereas subsequent studies20-22 have persuasively indicated that pharmacologic therapy can improve survival in heart failure, others have cogently and unhappily demonstrated the capacity for treatment to increase morbidity and shorten survival, thereby highlighting the potential for therapeutic misadventure.23-25 Ironically, it is now evident that in patients with advanced symptoms, treatment strategies exist that may produce symptomatic benefit on the one hand yet impair survival on the other.
Left ventricular dysfunction stimulates a host of neurohumoral compensations that appear fundamentally important in the expression of the heart failure syndrome. Experimentally and clinically, it appears that activation of the sympathetic nervous system with elevation in plasma norepinephrine occurs before activation of the renin-angiotensin-aldosterone axis. 26 In approaching optimal therapy for patients with heart failure, it is desirable to preserve or restore normal sinus rhythm so that atrioventricular synchrony exists with optimal atrioventricular delay. 46 Optimal electrical/mechanical performance and heart rate control may ultimately require placement of a cardiac pacemaker.47 Despite the relatively high incidence of ventricular arrhythmia and sudden unexpected death in heart failure, antiarrhythmic agents cannot be recommended in the post-CAST era.11,48 Although there are some grounds for optimism regarding the ability of ,8-blockers and amiodarone to reduce the incidence of sudden death in patients with heart failure, no prospective, randomized data are currently available to justify broad application of this strategy, although a survival trial on amiodarone in heart failure is in progress49,50 (Table 1 ). This has led to the suggestion that the automatic implantable cardioverter-defibrillator may provide a better alternative. However, a recent singleinstitution report of 68 consecutive patients treated with the automatic defibrillator for ventricular tachycardia or fibrillation provided sobering information for patients with ejection fractions <30%.51 Surgical mortality in this group was 11%, and they had a 57% survival during a 31-month follow-up period. The majority of the deaths were nonsudden, raising the concern that device therapy may simply convert the mode of exit of patients with advanced left ventricular dysfunction rather than alter the final result. The incidence of embolic complications in heart failure is known to be increased, and systemic anticoagulation has traditionally been advised. problem suggest that as many as 2% of women and 4% of middle-aged men have clinically important sleep apnea and that heart failure affects at least 1% of the population, coexistence of these two entities is likely in a significant proportion of individuals.55 Nasal continuous positive airway pressure not only is effective in curing the sleep apnea but in preliminary studies appears to result in improved functional class and ejection fraction in patients with symptomatic cardiomyopathy. 54 The mechanisms whereby improvement in cardiac function occurs in this context may be reduction of left ventricular afterload, attenuation of sympathetic surges during sleep, and improvement in hypoxemia. Pharmacologic Therapy Treatment objectives associated with drug therapy for heart failure include the reduction of central circulatory congestion and/or edema and the improvement of systemic perfusion. Other desirable aims include the reduction of myocardial oxygen consumption, enhancement of coronary perfusion, slowing of rapid heart rate, restoration of baroreceptor function, reversal of neurohumoral activation, restoration of cardiac size and shape, promotion of cardiac and vascular repair, and enhancement of survival.41 '56 Diuretics Diuretics remain a mainstay of heart failure treatment when fluid retention or central circulatory congestion is present. These agents are usefully classified according to their predominant site of action, ie, proximal tubule, loop of Henle, distal convoluted tubule, or collecting duct, and a further refinement of this classification can be undertaken based on their mode of action at each site. 57 The loop-active diuretics, consisting of furosemide, bumetanide, and ethacrynic acid, block the majority of active sodium chloride transport and are effective even when glomerular filtration rate is low. Diuretics acting at the distal tubule, such as hydrochlorothiazide and metolazone, are longer acting but less powerful than loop-active diuretics and more dependent on glomerular filtration rate for their effectiveness. Agents acting on the collecting duct tend to be relatively weak diuretics, but their potassium-conserving properties through either direct inhibition of Na-H exchange (thereby reducing potassium secretion) or direct antagonism of the effects of aldosterone, ie, spironolactone, can be usefully exploited in combination with other agents. When hyperaldosteronism is present, however, the diuretic potential of spironolactone may be substantially enhanced. 58 Renewed interest in the use of this agent has arisen because of its impressive ability to inhibit aldosterone-mediated myocardial fibrosis in experimental animals.59 A pilot study to evaluate the safety of aldactone in patients with class III or IV heart failure receiving an ACE inhibitor and diuretics is currently in progress with a view to a subsequent large-scale study of aldactone on mortality in heart failure (Table 1) (B. Pitt, personal communication, July 1993).
When heart failure is severe and large doses of diuretics in isolation become ineffective, additional strategies may be useful: (1) constant infusion of loopactive diuretics providing large doses at relatively low infusion rates may increase efficacy and reduce side effects; (2) combination of diuretics acting at different sites may provide synergism; this is especially true with the addition of loop-active diuretics to thiazides, which appears to increase thiazide-sensitive NaCl transport in the distal convoluted tubule; and (3) the use of diuretics may be potentiated by the infusion of renal doses of dopamine to increase renal blood flow. 57 Diuretics carry with them certain untoward effects that require clinical wariness. These include electrolyte imbalance in the form of hypokalemia and hypomagnesemia, both of which may potentiate digitalis intoxication and other ventricular arrhythmias. Hyponatremia with attendant activation of the renin-angiotensin system may develop. Overzealous use of diuretics and failure to respond to changing clinical circumstances may result in dehydration and prerenal azotemia. Vigilant clinical and laboratory monitoring, reduction of the dose when concomitant vasodilators are added, self-adjustment of diuretics, and intermittent dosing based on body weight changes monitored at home coupled with informed outpatient surveillance may be rewarded by avoidance of frequent hospitalizations for heart failure exacerbations. The use of diuretics for central and peripheral circulatory congestion remains a cornerstone of heart failure therapy, and evidence now exists to support their concomitant use with ACE inhibitor therapy.60 Potentiation of the effects of endogenous atrial natriuretic factor through the use of an endopeptidase inhibitor in nine class III and IV heart failure patients has recently been shown to produce impressive natriuresis and diuresis, decline in left ventricular filling pressure, and plasma norepinephrine, offering potential promise for novel therapy.61
Vasodilator Therapy
The introduction of vasodilator therapy for patients with congestive heart failure was a therapeutic milestone. Remarkable hemodynamic benefit was evident in advanced heart failure with initial use of intravenous infusions of phentolamine, nitroprusside, and nitroglycerine.62-64 The demonstration of drugs with purely peripheral mechanisms of action rapidly led to the introduction and testing of a host of such agents administered orally to patients with heart failure, and sublingual nitroglycerin emerged as useful emergent therapy for acute pulmonary edema.65 Controversy has marked the role of long-acting nitrate therapy in heart failure because of a relative paucity of adequately sized doubleblind placebo-controlled studies and because of concerns of nitrate tolerance.66-68 The An impressive body of evidence exists attesting to the efficacy of ACE inhibitors and their ability to improve symptoms, hemodynamics, and exercise performance in patients with heart failure. In 1987, the CONSENSUS investigators reported a landmark study of ACE inhibitors that revealed a 31% reduction in mortality in patients with functional class IV heart failure treated with enalapril. 20 The benefit in mortality was related to a reduction in death from progressive heart failure and was associated with a reduction in heart size and in requirement for other heart failure medications and with a significantly greater increase in the serum sodium level. Within 5 years of the CONSENSUS study, a remarkable series of publications reporting on the efficacy of ACE inhibitors in large-scale clinical trials emerged. The Veterans Administration Study Group undertook a second study using the hydralazine nitrate combination that had been the best therapy in VHeFT-1 as a reference standard to compare enalapril 20 mg daily in patients with mild to moderate heart failure. 22 In this study, VHeFT-II, enalapril resulted in a 28% lower mortality at 2 years, which was largely attributable to a reduction in sudden death among those patients who were least severely symptomatic: it is of particular interest that enalapril was able to decrease both the persistence of baseline ventricular tachycardia after 3 months of therapy and the emergence of new ventricular tachycardia at 1 and 2 years of follow-up, thereby paralleling the reduction in sudden death observed in the overall study.74 Although the hydralazine nitrate combination was superior to enalapril in increasing oxygen consumption at peak exercise and providing a greater increment in ejection fraction, this did not translate into a survival advantage. This finding has particularly important mechanistic implications in that it suggests that the survival advantage achieved by enalapril was secondary to a nonperipheral vasodilator mechanism perhaps mediated by antagonism of vasoconstrictor neurohormones, metabolic effects, and direct cardiac and/or coronary vascular protection. One disadvantage of the hydralazine nitrate combination, ie, 300 mg per day hydralazine and 160 mg isosorbide dinitrate, is patient compliance, with approximately one half of patients discontinuing or reducing the dose of one or the other of the medications. The SOLVD investigators, in a placebo-controlled trial of symptomatic heart failure patients, also demonstrated a survival benefit with enalapril treatment of 16% risk reduction, although approximately one third of patients in the active treatment arm had stopped enalapril by the end of the study.21 Importantly, these investigators demonstrated a parallel benefit on frequency of hospitalization for worsening heart failure and a survival benefit largely attributable to a reduction in progressive heart failure in patients with low ejection fractions. Approximately 1 year later, the SOLVD investigators reported on the prevention arm of their study, which examined in a placebo-controlled fashion the effects of enalapril on patients with functional class I or II heart failure and left ventricular ejection fractions of 535% who were not receiving drug treatment for heart failure.75 Although no significant reduction in mortality was seen over the average follow-up of 37 months, there was a 20% reduction in hospitalization for new or worsening heart failure in enalapril-treated patients that was most pronounced among patients with the lowest ejection fractions. An unexpected and interesting finding from the SOLVD study was that on composite analysis of both treatment and prevention arms, enalapril reduced the frequency of both myocardial infarction (23%) and unstable angina (20%). 76 The unfavorable survival rates evident in symptomatic patients with heart failure also prompted examination of the benefits of ACE inhibitor therapy early after myocardial infarction in patients without symptoms. flosequinan daily has recently been terminated earlier than planned because of the finding of excess mortality in the flosequinan group (M. Packer, personal communication, July 1993). The direct chronotropic action of this agent, which is independent of its blood pressurelowering effect; its potential for accumulation in congestive heart failure; and its nonspecific phosphodiesterase inhibitor action may have been influential factors on this result. 89 Recent interest in the investigation of novel vasodilators in heart failure has focused on the endogenous substance prostacyclin, which is known to produce vasodilatation of both pulmonary and systemic arterial as well as peripheral venous beds, with commensurate reduction in both preload and afterload of both ventricles. Its additional favorable cardiovascular profile, ie, inhibition of platelet aggregation, direct cytoprotection, and smooth muscle cell proliferation inhibition, coupled with preliminary favorable short-term hemodynamic studies in humans, stimulated the development of a large-scale survival trial to investigate prolonged infusion of prostacyclin in patients with refractory severe congestive heart failure. [96] [97] [98] This trial has been terminated earlier than planned because of excess mortality in the treatment group (R. Califf, personal communication, July 1993). Noteworthy in this regard in an initial clinical study of prostacyclin in heart failure was the finding of an increase in plasma epinephrine and heart rate. 98 
Inotropic Therapy
Perhaps the most distinguishing feature of inotropic therapy for heart failure is the chasm that has developed between expectations and achievement. If (Table 1) .
short term benefit, has been plagued by the development of an unfavorable side-effect profile, including acceleration of heart rate, accentuation of cardiac rhythm disturbances, and attenuation of efficacy.99-'03 Although intravenous dobutamine can produce dramatic short-term clinical and hemodynamic benefit, attempts to translate this into an outpatient strategy for sustained management with intermittent infusions were met with increased ventricular arrhythmias and mortality.'04,"05 A similar legacy of problems has greeted attempts to reduce degradation of cAMP through the use of phosphodiesterase inhibitors such as enoxamine and, most recently, milrinone.23 25 The excess mortality associated with milrinone in a large survival study, which was primarily sudden and probably mediated by proarrhythmia, coupled with smaller previous studies of similar inotropic agents, helped close the door on this approach to the long-term therapy of heart failure.106 '107 Given the suggestion that advanced heart failure should be perceived as a state of energy starvation or a cardiomyopathy of overload on the one hand and that excessive endogenous catecholamine activity is associated with downregulation of /31-receptors on the other, it is perhaps not surprising on reflection that further sustained inotropic stimulation seems harmful.108 Our knowledge here is incomplete, however, and confounded by the fact that a number of inotropic agents have peripheral vasodilating effects that are beneficial and that dose-response relations of their diverse effects across heterogeneous subsets of patients with heart failure are poorly characterized, with the result that the balance between benefit and harm in individual patients of studies is difficult to discern. Moreover, in facing the challenge of advanced refractory heart failure, the practicing physician, after discussion with the patient, may be justified in using a therapy that achieves symptomatic relief despite an unfavorable impact on survival.
Additional inotropic agents with distinctive mechanisms of action are undergoing active investigation. Vesnarinone (OPC-8212) has a complex and diversified mechanism of action that both affects ion channels and increases the inward calcium current through mild inhibition of phosphodiesterase.109 Initial studies by Feldman and coworkers109 indicated clinical benefit in a small randomized trial, which stimulated the conduct of a larger study in patients with advanced class III or IV heart failure. The investigators then examined two doses of vesnarinone, ie, 60 mg and 120 mg, against placebo in a randomized permuted-block design for 6 months in class III heart failure patients with ejection fraction c30% (mean, 20±6%), of whom 90% were on digoxin and ACE inhibitors. Although the 120-mg arm of the study was terminated earlier than planned because of a twofold increase in mortality, paradoxically, patients in the 60-mg arm showed a 50% (95% CI, 20% to 69%) reduction in the risk of worsening heart failure or death compared with the placebo arm (15% mortality at 28 weeks), emphasizing both the narrow therapeutic range of this agent and the peril of judging drug efficacy at a single dose."10 Although there was an overall 62% (95% CI, 28% to 80%) reduction in allcause mortality, this was coupled with an important side effect of reversible neutropenia, which occurred in 2.5% mechanism of benefit is unclear but may relate to its effects as an antiarrhythmic or cytokine inhibitor."' Further studies of this and related agents are warranted. Pimobendan is another new inotropic agent that has some phosphodiesterase inhibitory and vasodilator activity but is also known to sensitize the contractile apparatus to intracellular calcium.12 Kubo et al,"2 in a randomized blinded study of three doses of pimobendan in heart failure patients who were symptomatic despite digitalis, diuretics, and vasodilators, found significant increases in exercise duration and peak Vo2 as well as an improvement in quality of life and reduction in hospitalization rates. This agent was well tolerated and did not increase plasma norepinephrine or show evidence of proarrhythmia. Interestingly, the intermediate 5-mg dose achieved better results than the peak dose, which had previously shown the largest hemodynamic improvement, highlighting once again the difficulty in establishing the optimal dose of a new drug in heart failure with multiple effects. Additional safety and efficacy studies on this agent are required before its ultimate role is clear.
Ironically, digitalis, the longest-surviving inotropic and revealed a significant decrease in the frequency of metoprolol-treated patients deteriorating to the point of achieving heart transplantation criteria (19 placebo and 2 metoprolol patients, P=.0001). In addition, there was a marginally significant 34% reduction in the composite end point of death or need for transplantation (ie, 25 events in metoprolol versus 38 in placebo, P=.058; 95% CI, 6% to 62%) (K Swedberg, personal communication, August 1993).126 Some evidence exists to suggest that preferential benefit accrues to patients with idiopathic dilated cardiomyopathy as opposed to those with heart failure secondary to coronary artery disease.126 Proposed mechanisms for benefit of (-blocker therapy include reduction in sympathetic nervous activity, restoration of the p1-cardiac receptor population with improved contractile performance, enhanced myocardial relaxation, and improved cardiac efficiency associated with a reduction in heart rate. The addition of digoxin to the medication of patients with symptoms persisting on combined ACE inhibitor and diuretic therapy is a logical next step, although the addition of nitrates and/or hydralazine is another alternative. Patients unable to tolerate ACE inhibitor therapy should be offered the option of combined hydralazine nitrate therapy. In refractory heart failure, the addition of (initially) low-dose metoprolol therapy, especially in those patients with congestive cardiomyopathy and resting tachycardia, may be useful. A contemporary heart failure paradigm is illustrated in the Figure and undertakes to define therapeutic goals according to symptomatic status. Importantly, this demonstrates that there is a quartet of therapeutic goals, the relative importance of which depends on the symptomatic status of the patient and expectations concerning the natural history. As patients become progressively more symptomatic, with declining life expectancy, therapeutic priorities focus more on relief of symptoms and prevention of complications. The threshold for accepting greater risk to achieve benefit under such circumstances is diagonally depicted as rising, indicating a willingness to accept more risk to achieve benefit in patients with advanced symptoms. By contrast, in patients who are asymptomatic with minimal impact on survival, choice of therapy should be directed toward improvement in survival and halting progression of or reversing the disease. At this point in the evolution of the disease, one is not willing to tolerate substantial risk to achieve benefit.
In Table 2 , a summary of recently published placebocontrolled survival trials aimed at reducing morbidity and mortality from heart failure is shown. The study drug, patient characteristics at entry, average ejection fraction at baseline, mean follow-up time, and placebo mortality are shown. As is evident from the relative risk in the right column, although the vasodilator trials show a survival benefit, substantial residual mortality exists in the treatment group, which indicates the need for future progress in the treatment of heart failure. Importantly, four trials that have had negative effects on survival used agents that increased resting heart rate, ie, the Xamoterol and Promise trials, and the recently concluded survival trials with flosequinan and prostacyclin. This tendency for an increase in heart rate, with a propensity for accentuation of ventricular arrhythmias and unfavorable neurohumoral activation, is reminiscent of the negative clinical experience with other phosphodiesterase inhibitors and j3-agonists.
A discussion of mechanical assist devices, cardiomyoplasty, and cardiac transplantation as approaches to the heart failure syndrome is beyond the scope of this review. Although important gains in survival have been achieved by cardiac transplantation, continuing problems with rejection, heart failure, sepsis, accelerated atherosclerosis, and psychosocial adjustment remain a concern and pose opportunities for creative solutions. 129 Despite the enormous explosion in our knowledge concerning treatment opportunities in heart failure, we remain ignorant about many aspects of the syndrome and the agents that modify it. Heterogeneity of patients and etiologies and differing mechanisms of action of the same drugs with different dose-response relations for each remain important components of the problem. Fresh approaches rigorously tested and derived from the basic laboratory will be required to meet the enormous challenges ahead. Table 3 depicts a proposed future agenda for advances in heart failure.
